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Abstract
In a mouse model for molybdenum cofactor deficiency as an example for an inherited metabolic
disease we have determined the dosage of recombinant AAV necessary to rescue the lethal
deficiency phenotype. We demonstrated long-term expression of different expression cassettes
delivered in a chimeric AAV capsid of serotype 1/2 and compared different routes of application.
We then studied the effect of double and triple injections at different time points after birth and
found a short neonatal window for non-response of the immune system. Exposition with rAAV
capsids within this window allows transgene expression after a second rAAV transduction later.
However, exposition within this window does not trigger immunotolerance to the viral capsid,
which limits rAAV-mediated refurbishment of the transgene to only one more application outside
this permissive window.
Findings
In mammals, molybdenum cofactor (MoCo) is essential
for the activity of sulfite oxidase, xanthine dehydrogenase
and aldehyde oxidase [1]. The gene products of the
human genes MOCS1, MOCS2, MOCS3 and GEPH are
required for the biosynthesis of MoCo [2]. A mutational
block of these genes leads to MoCo deficiency (OMIM
#252150) associated with a progressive neuronal damage
and death before adolescence in affected patients. The
majority of patients suffer from type A deficiency and har-
bour mutations in the gene MOCS1 [3].Mocs1 knockout-
mice show no detectable residual Mocs1 mRNA levels and
display a severe phenotype reflecting the biochemical
characteristics of human MoCo-deficient patients [4].
Recently, we described the phenotypical rescue of Mocs1-
deficient mice by intrahepatic injection of a recombinant
adeno-associated virus (rAAV) vector carrying an expres-
sion cassette for the human MOCS1 cDNA [5]. The
MOCS1 expression cassette has been describe before and
essentially contains a hybrid promoter consisting of a
cytomegalovirus (CMV) enhancer, a human β-actin pro-
moter, exons 1 through 10 of the human MOCS1 gene, a
deleted intron 9, which allows for alternative splicing
leading to the gene products MOCS1A and MOCS1B and
a bovine growth hormone (BGH) polyadenylation (poly
A)-signal. MOCS1A and MOCS1B together produce the
relatively stable intermediate cPMP, which is further proc-
essed to active MoCo by the products of the genes
MOCS2, MOCS3 and GEPH.
Transfer of the MOCS1 gene was primarily aimed at trans-
duction of hepatocytes, since the liver is the primary organ
involved in detoxification of sulfite to sulphate by sulfite
oxidase [6]. In the meantime, mice rescued by the intrahe-
patic rAAV-MOCS1 reached a lifespan of up to 666 days.
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To study the long-term expression profile after AAV trans-
duction, we here analyzed wild-type mice, which had
received an intrahepatic injection of AAV encoding the
green fluorescent protein (AAV-EGFP) on day 6 after birth.
The  EGFP  expression cassette contains the coding
sequence for EGFP instead of the MOCS1 cDNA.
Recombinant viruses were generated by using a mixture of
AAV helper plasmids encoding serotype 1 and 2 in ratio of
1:1. Previous studies had demonstrated that the chimeric
AAV1/2 vector triggers a higher expression level both in
liver and in muscle as compared to serotypes 1 or 2 [7].
Figure 1 shows that the intrahepatic application using
AAV1/2 capsids leads to predominant expression in heart
and liver, where the transgene product is detectable for
more than 10 months. However, the rate of transgene
expressing cells drops down from almost 100% in liver [5]
to approximately 5%, while in the heart after 10 months
still approximately 50% of cells expressed EGFP (figure 1).
A similar expression profile has been observed in mice
carrying the EGFP  expression cassette in all cells after
microinjection of fertilized oozytes and subsequent
breeding (data not shown), which indicates that not the
rate of transduction but rather persistence of expression
accounts for this organ-specific difference.
As a further approach to the treatment of patients, we
investigated the efficacy of systemic AAV delivery. Com-
parative studies 1 month after rAAV-EGFP  application
showed similar tissue transduction after either intrahe-
patic or intravenous injection [5]. Using the MOCS1
expression cassette in an AAV 1/2 capsid, we here studied
the effect of systemic delivery by tail vein injections. For
this application we used mice with a minimum body
weight of around 15 g corresponding to an age of approx-
imately 40 days. Untreated Mocs1 deficient mice are una-
ble to build cPMP, the first intermediate in the MoCo
biosynthesis, and die on average 7.5 days after birth [4].
We pretreated Mocs1-deficient mice until day 40 with peri-
odic intrahepatic injections of purified cPMP from
Escherichia coli [8] to achieve a suitable size for tail vein
injection.
Intrahepatic injections were done every other day with
increasing amounts from 2 μg in the first week up to 32 μg
from the 5th week onward. On day 40, they received 4 ×
109 tu AAV-MOCS1 by a single intravenous injection (n =
5). Control animals (n = 10) received the rAAV vector, in
which the MOCS1 cDNA was replaced by the fluorescent
reporter EGFP cDNA. These controls died on average 11
days after the final cPMP injection. In contrast, none of
the mice treated with AAV-MOCS1 died from MoCo defi-
ciency. Two of them have reached a life span of approxi-
mately 500 days without cPMP supplementation (figure
2, blue line). The other three mice were sacrificed in the
course of reapplication studies (see below).
Considering the lower dosage of 4 × 109 tu AAV-MOCS1
for systemic delivery, as compared to 1 × 1010 tu for the
intrahepatic injections described previously [5] and
above, the results described here indicate a similar efficacy
for both application schemes. All five above described
mice had been mated and were fertile. The offspring (n =
64) died on average on day 5.35 after birth, which corre-
sponds to the lifespan of untreated homozygous Mocs1
knockout mice from matings of heterozygous mice. This
is indirect evidence that the intravenous tail vein injec-
tions did not result in germ line transmission of the vector
genome.
To estimate the necessary dosage for the treatment of
humans, we determined the minimal dosage required to
rescue the deficiency phenotype via the intravenous route.
20 neonatal Mocs1-deficient mice were pretreated with
purified cPMP as described above. At day 40 after birth,
the animals obtained a single intravenous tail vein injec-
tion containing various amounts of AAV-MOCS1 in phos-
phate-buffered saline. First, we investigated the effect of a
thirty-fold reduced dosage of AAV-MOCS1 as compared to
the experiments described above, i.e. 1.5 × 108 tu (n = 8).
Mice of this group died on average 28.75 ± 6.5 days after
the AAV-MOCS1 injection and discontinuation of cPMP
substitution (figure 2, red line). This reduced dosage
apparently is not sufficient to rescue the lethal phenotype.
Next, we studied the effect of an intermediate dosage of 4
× 108 tu AAV-MOCS1 on day 40 after cPMP pre-treatment
(n = 12). The mice of this group died on average 238.5 ±
124.4 days after AAV-MOCS1 injection and cPMP with-
drawal at day 40 after birth (figure 2, green line). All ani-
mals of this group were mated and all but one were fertile.
Again, the offspring died within the range of untreated
animals (data not shown). The observed high variance of
the life span suggests that the intermediate dosage of 4 ×
108 tu AAV-MOCS1 represents a borderline result and
indicates a range for the minimal dosage required for
abolishing the MoCo deficiency phenotype. With a maxi-
mum body weight of 40 g for the mice used here this
would correspond to 1 × 1010 tu per kg body weight. A one
year old child with a body weight of 10 kg thus would
require 1 × 1011 tu of AAV-MOCS1, which is within the
range of GMP production facilities.
Although one single injection could abolished the pheno-
type of the MoCo-deficiency, our murine model allows a
prediction only for the natural life span of mice, i.e. 2 to 3
years. In contrast to long-lasting expression in mice, rats,
hemophilic dogs and nonhuman primates, expression at
therapeutic levels in humans was limited to a period ofGenetic Vaccines and Therapy 2009, 7:9 http://www.gvt-journal.com/content/7/1/9
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Long-term expression after AAV1/2 transduction Figure 1
Long-term expression after AAV1/2 transduction. Wild-type mice obtained a single intrahepatic AAV-EGFP injection 
containing 4.5 × 109 tu on day 6. After 10.5 months the mice were perfused with 4% paraformaldehyde. Tissue for expression 
analysis was cryoprotected in sucrose and stored frozen at -80° until analysis. Cryostat sections of 3 μm thickness were pre-
pared for EGFP expression analysis. Pictures were recorded by Fluorescent microscope BX60 from Olympus. Fluorescence is 
shown as an overlay of EGFP (green) and nuclear DAPI (blue) fluorescence. The images were recorded with an exposure time 
of 50 ms for DAPI and 500 ms for EGFP (1 s for negative expression).Genetic Vaccines and Therapy 2009, 7:9 http://www.gvt-journal.com/content/7/1/9
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around 8 weeks [9-14]. This difference was mainly attrib-
uted to prior infection of the human patients with natural
AAVs in combination with helper adenovirus [15]. This
leads to formation of memory CD8+ T cells and their acti-
vation upon reexposure to the AAV capsid.
Thus, the possibility of repeated vector administrations in
the treatment of patients from an immunological point of
view is an important issue to be addressed. To this end, we
investigated the feasibility of successful rAAV re-adminis-
tration at different time points in the MoCo deficient
mouse model and compared the reapplication possibili-
ties in different developmental stages. AAV serotype 1/2
(in a 50:50 ratio) was used throughout.
In the first experiment, two Mocs1-deficient mice were pre-
treated for 40 days after birth with purified cPMP as
described above. At day 40, the two animals obtained a
single intravenous tail vein injection of 65 μl containing 4
× 109 tu AAV-MOCS1. The successful transduction of this
first injection was confirmed by the prolonged lifespan of
the otherwise MoCo-deficient animals. The mice were
injected for the second time after three months with an
AAV vector carrying a reporter gene vector (4 × 109 tu
AAV1/2-EGFP). As a positive control for the second injec-
tion, two wild-type mice obtained only 4 × 109 tu AAV1/
2-EGFP. The negative controls were two wild-mice with-
out any treatment. Two months after AAV1/2-EGFP injec-
tions, all six mice were perfused with paraformaldehyde.
The second AAV injection did not result in any observable
expression of EGFP in the liver (figure 3).
Studies on hemophilia B mice showed that in utero or neo-
natally AAV-treated mice do not develop antibodies to the
AAV capsid after the first injection [16]. They demon-
strated that it is possible to establish tolerance to the trans-
gene product human factor IX by these early injections
and to obtain long-term therapeutic levels in immuno-
competent mice. Here, the transgene products of the
MOCS1 expression cassette are localized intracellular and
thus not accessible for antibodies. We therefore concen-
trated on the existence of a "window of opportunity" to
induce tolerance against the viral capsid in repeated expo-
sures.
De-escalations studies of AAV1/2-MOCS1 delivery Figure 2
De-escalations studies of AAV1/2-MOCS1 delivery. Survival of Mocs1-deficient mice injected i.v. on day 40 after birth 
with various amounts of AAV-MOCS1. Group A (blue) was injected with 4 × 109 tu (n = 2). Group B (red) received 1.5 × 108 
tu AAV-MOCS1 (n = 8). Group C (green) received a single injection containing 4 × 108 tu (n = 12).Genetic Vaccines and Therapy 2009, 7:9 http://www.gvt-journal.com/content/7/1/9
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Three groups of two Mocs1-deficient mice each received an
intrahepatic injection of 50 μl containing 1 × 109 tu AAV-
MOCS1 on day 1, day 10 or day 20, respectively. The mice
were injected for the second time three months after the
first injection with 50 μl containing 1 × 109 tu AAV-EGFP.
Two wild-type mice served as negative controls and
obtained no second injection. Additionally, for each time
point two wild-type mice served as positive control for the
AAV-EGFP injections and obtained only the second injec-
tion with 1 × 109 tu AAV-EGFP. Two months after the
AAV-EGFP  injections, all mice were perfused with 4%
paraformaldehyde. The groups with the first injection at
day 10 or day 20 the second injection of AAV-EGFP did
not result in any observable expression of EGFP in the
liver (figure 4a, b). In the group injected first at day 1 after
birth, both mice showed strong EGFP-expression (figure
4c), which confirms that the immune system shortly after
birth does not react to the vector capsid.
Since the products of the MOCS1 and the EGFP expres-
sion cassette do not share cross-reacting epitopes, we
could investigate the potential of early injections to
induce an immune tolerance against the viral capsid by
triple injections. Two wild-type mice obtained a first int-
rahepatic injection of 1 × 109 tu AAV-MOCS1 on day 1
after birth and a second injection with 1 × 109 tu AAV-
MOCS1 on day 10. After two months they received a third
injection of 1 × 109 tu AAV-EGFP. A positive control for
the AAV-EGFP injections obtained only a single injection
of 1 × 109 tu AAV-EGFP. Two months after AAV-EGFP
injections, all mice were perfused with 4% paraformalde-
hyde. Here, the rAAV-EGFP injections did not lead to an
EGFP expression (figure 4d), even though the first expo-
sure to AAV1/2 capsid occurred on day 1 after birth (com-
pare figure 4c). While the role of a cytotoxic T-cell
response in mice remains unclear, the immune system
clearly built neutralizing antibodies (nABs) [17,18]
against the viral vector after the second injection of viral
vector. Thus, the early exposure of the immune system to
viral vector capsid allows a successful second application
but does not induce an immunotolerance against the cap-
sid proteins.
An important factor in nAB response is the time point of
viral vector administration. The group of Petry et al [19].
showed that the efficacy of readministration is dependent
on the titer of nAB and that the level of nABs is propor-
tional to the virus dose used for the first injection. Since
repeated AAV treatment in adolescence leads to immune
responses, future experiments will have to show whether
the combination of early first exposure, a lower dosage of
virus and/or temporary immunosuppression (e.g. with
cyclosporine) facilitates more successful rAAV reapplica-
tions.
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Vector reapplication in adolescence Figure 3
Vector reapplication in adolescence. Liver sections of adult mice after different treatment schemes. Exposure times (exp.) 
for EGFP are indicated (for further details see figure 1). A) First injection i.v. on day 40 with AAV-MOCS1, second injection int-
rahepatic with AAV-EGFP after 3 months. B) Only one intrahepatic AAV-EGFP injection 4 months after birth. C) No injection.Genetic Vaccines and Therapy 2009, 7:9 http://www.gvt-journal.com/content/7/1/9
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Reapplication at different developmental stages Figure 4
Reapplication at different developmental stages. EGFP expression two months after AAV-EGFP injection (filled triangles) 
following AAV expositions (open triangles) at different developmental stages. Animals received intrahepatic AAV-MOCS1 injec-
tions as indicated on top of the lines and an intrahepatic AAV-EGFP injection 2 months after the last AAV-MOCS1 injection. 
Liver sections of 2 animals are shown for each time point. Positive control animals (+) received only an AAV-EGFP injection. 
Negative controls (-) received no AAV. Further details are describe in figure 1.Publish with BioMed Central    and   every 
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